EGFR and non-small cell lung carcinoma: Previous studies in NSCLC patients also showed an early (2–14 days) reduction of 18F-FDG uptake in response to treatment with EGFR TKIs [11–14] that was predictive of morphovolumetric tumor response, PFS, and OS.